◈ Nootpedia

This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: thorough Compound OPTIONAL-ADD MEDIUM

Egcg (Green Tea Extract)

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Editor's verdict OPTIONAL-ADD MEDIUM

"Useful adjunct as part of a daily green-tea catechin intake or a focused metabolic-support stack (with L-theanine or caffeine), but high-dose extract supplementation carries real hepatotoxicity risk — especially when taken fasted, as a bolus, or in concentrated extract form. For a 20yo athlete with no caffeine baseline, drinking 2-3 cups of brewed green tea daily captures most of the benefit without the risk; EGCG capsule supplementation is only worth it for specific goals (fat-loss cut, metabolic support) and should be food-paired."

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • 20yo MMA athlete, no caffeine baseline (this archetype)
    POSSIBLE

    Drinking 1–2 cups of brewed green tea or 1 g matcha/day = clean win — modest cardiovascular + antioxidant + L-theanine benefit, ~100–300 mg EGCG in food matrix, near-zero risk. Isolated EGCG extract supplementation: skip during off-season, possibly run during a defined cut phase at 270–400 mg/day with food + ALT/AST monitoring + HLA-B*35:01 status verified post-23andMe. The user's V4 stack already covers most of the polyphenol + antioxidant + cardiovascular bases via curcumin, omega-3, and rhodiola, so isolated EGCG is redundant for general use. Drink the tea, save the pills for a metabolic protocol.

  • Athletic male 18–35, body composition focus (cut / recomp phase)
    POSSIBLE

    EGCG + caffeine 30–60 min pre-training during a 12-week cut. Real but modest fat-loss signal (~1–2% body fat over the cycle). Stack: 270 mg EGCG + 150 mg caffeine + small protein meal. Monitor ALT/AST. Decaf extracts if already getting caffeine from coffee/preworkout to avoid stacking.

  • Female 18–45, menstruating, mixed-diet
    POSSIBLE

    with caveats. Tea is fine; extracts: separate from iron-rich meals by ≥1 hour, pair with vitamin C. Avoid in pregnancy / lactation (folate antagonism + insufficient safety data on high doses). Watch ferritin if heavy tea drinker.

  • Pregnant / breastfeeding
    CAUTION

    Limit to 1–2 cups brewed green tea/day max. Avoid extract supplements entirely. Folate antagonism is a theoretical but plausible concern.

  • Liver disease, elevated baseline ALT/AST, hepatitis, NAFLD
    SKIP

    isolated high-dose extract. Brewed tea may still be fine in moderation; consult hepatologist. Avoid stacking with hepatotoxic medications.

  • Stimulant user (amphetamines, modafinil, high-dose caffeine)
    CAUTION

    on isolated high-dose extract — theoretical COMT inhibition + cumulative cardiovascular load. Brewed tea + their existing stimulant is fine; high-dose Teavigo with daily Adderall is a flagged combination. The user (planned modafinil V5) — tea OK, but skip simultaneous high-dose EGCG capsules; the in vivo COMT effect is modest but the combination doesn't add clear benefit.

  • 50+, cardiometabolic risk reduction
    OPTIONAL ADD

    Modest LDL/BP/glucose meta-analysis signal is real. Brewed tea preferred over pills. Extract at 270 mg/day with food and LFT monitoring is reasonable. Watch interactions with statins, warfarin, beta-blockers.

  • HLA-B*35
    —

    01 carrier: SKIP isolated extract. Brewed tea fine. The personal genetic risk is the most actionable safety signal in the EGCG literature.

  • Cancer chemoprevention focus (high-risk family history, BRCA, etc.)
    OPTIONAL

    ADD with clinician oversight. Polyphenon E doses (~400–600 mg EGCG/day) have been used in NCI-funded prevention trials. This is the strongest case for higher-dose isolated supplementation, but should be discussed with an oncologist familiar with chemoprevention.

  • Iron-deficiency anemia / heavy menstrual bleeding / vegan
    CAUTION

    Separate tea from iron meals/supplements by ≥1 hour. Pair iron with vitamin C. Avoid extracts during repletion phase.

  • Drug-tested athlete (WADA, USADA)
    OK

    EGCG not on prohibited list. Avoid combination thermogenic products (often spiked with banned stimulants — synephrine, sibutramine analogs, etc.).

▸ Subjective experience (deep)

From brewed green tea (1–3 cups, ~30 mg caffeine + ~100 mg EGCG + 20–50 mg L-theanine per cup):

  • Smooth, alert, calm focus — the classic "L-theanine + caffeine" experience. EGCG itself doesn't produce a felt subjective effect at tea-level doses.
  • Mild diuretic effect.
  • Astringent mouthfeel (catechin tannin), some get tooth staining over time.

From matcha (similar but more concentrated, whole-leaf):

  • Higher caffeine + EGCG + L-theanine per serving than steeped tea.
  • 2–3 hour smooth alertness with much less crash than coffee.
  • Slightly grassy/umami taste.

From standardized EGCG extract capsules (typical 200–400 mg EGCG/dose):

  • Largely felt as nothing acutely. Most of the benefit is subclinical (body composition, biomarkers).
  • Some users report mild GI upset, especially if taken fasted.
  • Decaffeinated extracts (Teavigo, etc.) won't produce any stimulant-like effect — useful diagnostic that you can't tell whether the capsule is "working" except through downstream markers.

Honest variability: ~5–10% of EGCG-extract users get GI upset or nausea. Headaches are reported but rare. Subtle subjective signal is the rule.

▸ Tolerance + cycling deep dive
  • Pharmacological tolerance: Minimal. EGCG's mechanisms are mostly enzymatic (DNMT, AMPK, FASN) — these don't develop receptor-downregulation tolerance in the way GABAergics or dopaminergics do.
  • Behavioral / subjective tolerance: Doesn't apply meaningfully because EGCG isn't a "felt" compound at clinical doses.
  • Cycling recommendation: 8 weeks on / 2 weeks off for extract use, not for tolerance reasons but to (a) reduce cumulative hepatic load, (b) re-check ALT/AST cleanly, (c) reassess whether the supplement is producing meaningful biomarker change vs continuing baseline tea drinking.
  • Brewed tea: no cycling needed at 1–3 cups/day. Daily-forever is the wellness profile observed in green-tea-drinking populations (Japan, China — longevity correlations).
▸ Stacking deep dive

Synergistic with

  • caffeine (100–200 mg with 200–400 mg EGCG): The best-evidenced thermogenic + fat-oxidation stack. Most fat-loss meta-analyses are EGCG + caffeine, not standalone EGCG. Pre-training timing optimal.
  • l-theanine (already in tea matrix, ~20–50 mg per cup): Cognitive synergy (calm alertness) and physiologically anchors the EGCG-with-food preference.
  • vitamin C (100–500 mg): Stabilizes EGCG in GI tract, marginally improves bioavailability, and counteracts the iron-chelation effect when taken with iron-containing meals.
  • omega-3 / DHA-EPA: Complementary anti-inflammatory and cardiovascular signals; no direct interaction.
  • curcumin, resveratrol, quercetin: Polyphenol stack with overlapping AMPK/NF-κB/Nrf2 pathway effects. Modest additive effect on biomarkers; redundancy at high doses.
  • creatine, beta-alanine: Neutral co-administration; standard athletic stack overlap.

Avoid / use caution stacking with

  • Iron supplements / iron-rich meals: Separate by ≥1 hour. Especially relevant for menstruating women, vegans, and athletes with low ferritin.
  • Acetaminophen / paracetamol: Both hepatic; combined oxidative load on glutathione system. Avoid high-dose chronic combination, especially fasted.
  • Statins, isoniazid, methotrexate, valproate, amiodarone, other known hepatotoxic medications: EGCG extract supplementation adds hepatic insult to drugs that already have a DILI signal. Skip extract; tea is fine.
  • Strong stimulants (amphetamines, modafinil, high-dose caffeine): Theoretical COMT-inhibition potentiation. In vivo signal is small (Lorenz 2014) but interaction databases flag this. For a stimulant user, EGCG via tea is fine; high-dose isolated extract should be considered cautiously.
  • MAOIs: Theoretical pressor risk via prolonged catecholamine signaling; sparse human data. Caution warranted.
  • Anticoagulants (warfarin, DOACs): EGCG affects platelet aggregation and CYP enzymes involved in warfarin metabolism. Monitor INR if combining.
  • Bortezomib (myeloma chemotherapy): EGCG directly binds and inactivates bortezomib. Absolute contraindication.

Neutral

  • Most of the user's V4 stack (Mg, NAC, citicoline, PS, DHA, rhodiola, glycine, D3/K2, creatine, beta-alanine) — no interactions known.
  • L-theanine, l-tyrosine — neutral and often co-formulated.
▸ Drug interactions deep dive

EGCG's metabolic and interaction profile:

  • Substrate of: COMT (gets methylated), UGT1A4/UGT1A8 (glucuronidation), sulfotransferases (sulfation)
  • Modest inhibitor of: CYP1A2, CYP2C9, CYP3A4, CYP2C19; P-glycoprotein efflux pump (intestinal); organic anion transporting polypeptide (OATP)
  • Iron chelator in GI tract

Clinically meaningful interactions:

  1. Bortezomib (Velcade) — Absolute contraindication. EGCG directly binds and inactivates the boronate moiety of bortezomib, abolishing antimyeloma efficacy. Don't combine.
  2. Statins (atorvastatin, simvastatin, rosuvastatin) — Both CYP3A4 substrates; EGCG inhibition can mildly elevate statin levels. Additive hepatic load. Monitor LFTs if combining high-dose extract with statins.
  3. Warfarin — Vitamin K content in green tea (especially high in matcha) can reduce INR. Heavy tea drinkers on warfarin: stabilize intake and monitor INR.
  4. Iron supplements (ferrous sulfate, ferrous bisglycinate) — Reduced absorption. Separate by ≥1 hour. Vitamin C co-administration mitigates.
  5. Acetaminophen — Combined hepatic oxidative load on glutathione. Avoid high-dose acute combinations.
  6. Nadolol, atenolol (beta-blockers) — Reduced absorption via OATP inhibition. Take 4+ hours apart.
  7. Methotrexate — EGCG may inhibit dihydrofolate reductase additively. Avoid in patients on chronic MTX.
  8. Stimulants (amphetamines, modafinil) — Theoretical COMT inhibition prolongs catecholamine signaling. Practical effect modest in humans, but caution flag.
  9. Birth control / hormonal contraception — No documented efficacy reduction; theoretical CYP3A4 modulation but EGCG is a weaker modulator than e.g. St. John's Wort. Probably fine.
  10. MAOIs — Theoretical pressor risk; limited human data. Caution.
▸ Pharmacogenomics

The hepatotoxicity story is fundamentally a pharmacogenomic story — EGCG-DILI is predominantly idiosyncratic and immune-mediated, not strict dose-toxicity.

HLA-B*35:01:

  • ~16–20% of European-ancestry population are carriers. Higher in some Mediterranean and South Asian populations.
  • 5–7× over-represented in green tea-induced liver injury case series (PMID 32892374).
  • Mechanism: EGCG forms covalent adducts with hepatic proteins, presented by HLA-B*35:01 to CD8+ T-cells → T-cell mediated hepatocellular injury (Chem Res Toxicol 2024).
  • Practical: This allele is in standard 23andMe and most consumer genomic platforms. If the user is a carrier — skip high-dose isolated extract supplementation, stick to brewed tea (the case reports are virtually all extract-based, not tea-based).
  • For the user: confirm HLA-B status when 23andMe results land in June 2026.

COMT Val158Met (rs4680):

  • Met/Met (slow-COMT) carriers had significantly larger ALT/AST rises on 1315 mg/day GTE for 12 months in the Minnesota Green Tea Trial (PMID 36178169).
  • Mechanism: COMT is one of the primary EGCG metabolism pathways; slow COMT → higher unconjugated EGCG → higher hepatic exposure.

UGT1A4 polymorphisms:

  • Low-activity variants similarly increased ALT/AST response in MGTT.
  • Mechanism: parallel detoxification pathway.

For users in this archetype specifically: await 23andMe (~June 2026) and screen HLA-B*35:01, COMT Val158Met, UGT1A4 status before any decision to run isolated EGCG extract chronically. Brewed tea is genome-blind safe.

▸ Sourcing deep dive

Form-by-form

Form EGCG yield Cost Reliability Notes
Brewed green tea (bagged) 50–100 mg EGCG/cup; +30 mg caffeine; +20 mg L-theanine $0.05–0.30/cup High if Japan-sourced Sencha, gyokuro, hojicha. Japan-sourced safer for heavy metals than Chinese mass-market.
Brewed green tea (loose-leaf, premium) 80–150 mg EGCG/cup $0.50–2.00/cup High Higher EGCG per serving; better flavor.
Matcha (ceremonial, Japan) 100–200 mg EGCG/g + ~70 mg caffeine + ~40 mg L-theanine per gram $40–80/30g High (Japan) / Variable (China) Whole-leaf — you ingest everything in the leaf including any contaminants. Stick to Japan-origin with third-party heavy-metal testing (Ippodo, Encha, Nio, MatchaBar Encha). Avoid Chinese-mass-market matcha (32% of Chinese tea samples exceed lead limits per 2016 national survey).
Standardized GTE extract capsules (50–90% EGCG) 200–400 mg EGCG per cap typical $10–30/bottle Variable Look for: (a) % EGCG specified on label; (b) standardized to EGCG not "total catechins"; (c) third-party testing (USP Verified, NSF, ConsumerLab); (d) decaffeinated if caffeine sensitive.
Teavigo (Taiyo) Decaf, ~94% EGCG Premium pricing High Gold-standard pharmaceutical-grade decaf EGCG. Used in most clinical trials.
Polyphenon E Pharmaceutical-grade defined GTE Research-only mostly High Used in NIH-funded chemoprevention trials.

For the user specifically

  • Daily wellness: 1–2 cups Japan-sourced sencha or 1 g ceremonial matcha (early afternoon, given residual caffeine and the user's chronotype) — provides clean EGCG + L-theanine + minimal caffeine. Cost ~$2–4/day. Skip evening tea to protect sleep.
  • If running a cut phase later: Teavigo or USP-verified decaf GTE at 300 mg EGCG/day, with food, paired with V4 vitamin C, monitor ALT/AST at 4 and 8 weeks. Stop at any GI red flag.
  • What not to do: Bulk-bin generic Chinese GTE capsules from Amazon (heavy-metal risk + unclear EGCG standardization), fasted bolus dosing, daily-forever extract use without baseline LFTs.
▸ Biomarkers to track (deep)

Baseline (before starting extract supplementation)

  • ALT/AST — covered in June 2026 bloodwork panel. Hard prerequisite before running extracts >300 mg/d.
  • GGT, ALP, bilirubin — fuller hepatic picture if any concern.
  • Ferritin, hemoglobin, MCV — iron status, especially if vegetarian or menstruating.
  • TSH, fT4 — thyroid baseline.
  • Lipid panel + fasting glucose — biomarkers EGCG can modestly move.
  • hsCRP — anti-inflammatory mechanism endpoint.
  • HLA-B*35:01 + COMT + UGT1A4 status from 23andMe when results arrive — this is the most useful single screen.

During use (if running extract)

  • Week 4–8: ALT/AST recheck at 300+ mg/day chronic dose. Stop if any unexplained rise.
  • Subjective: GI tolerance, mood, energy, sleep.
  • Monthly weight + body composition if running for cut phase.

Post-cycle (after extract phase ends)

  • ALT/AST normalization (should restore within 4–8 weeks of stopping if any rise).
  • Lipid panel, fasting glucose delta vs baseline.
  • Subjective assessment: did body comp / energy / cardiovascular markers change in a way that justifies running another cycle?
▸ Controversies / open debates Live debate

1. "Brewed tea vs. extract supplement — equivalent or fundamentally different risk profile?"

  • Clinical view: Brewed tea is essentially safe across all populations and dosing patterns observed historically. Extract supplements have a clear and replicated hepatotoxicity signal. They are not equivalent. The case reports in the USP review and DILIN registry are dominated by extracts.
  • Marketing view: "It's just concentrated tea, what's the difference?" — wrong. Delivery matrix, peak hepatic concentration, fasted-vs-fed status, and dose all differ markedly.
  • Practical implication: When someone says "I want to take EGCG for benefit X," the correct first answer is almost always "drink more green tea" not "buy a Teavigo bottle."

2. "Is fasted dosing genuinely riskier or is this overblown?"

  • Conservative view: Yes, riskier. Multiple case series highlight fasted bolus as a recurring pattern; pharmacokinetic data shows 2–3× bioavailability gain fasted; mechanistic plausibility (high transient hepatic concentration → pro-oxidant flip).
  • Counter-view: Some clinical trial protocols use fasted dosing for absorption optimization without uniformly causing hepatotoxicity, so it's not deterministic.
  • Practical reconciliation: Fasted dosing increases risk substantially without delivering meaningfully better clinical outcomes. The only reason to do it is if you're maximizing bioavailability for a research protocol, and even then you'd want LFT monitoring. For everyone else: take with food.

3. "COMT inhibition by EGCG — real in vivo or in-vitro-only artifact?"

  • Old view: EGCG is a potent COMT inhibitor (IC50 0.07 μM in vitro); explains the thermogenic synergy with caffeine + ephedrine.
  • Lorenz 2014 challenge: 750 mg EGCG in humans didn't measurably impair COMT activity in plasma.
  • Probable reconciliation: EGCG is itself a COMT substrate, so it competes for the enzyme rather than purely inhibiting it. Net effect on catecholamine half-life is small in vivo. The "EGCG + caffeine fat-burner stack" works mostly via caffeine + AMPK, not via meaningful catecholamine prolongation.

4. "Telomerase downregulation — anti-aging or anti-cancer?"

  • Cancer-prevention view: Cancer cells often re-express telomerase to immortalize themselves; downregulating telomerase blocks one of cancer's hallmarks. This is the chemoprevention angle.
  • Longevity-bro view: Telomerase shortening is associated with aging, so we want more telomerase, and EGCG might be net-negative for longevity.
  • Practical answer: EGCG's telomerase effect is tissue- and concentration-dependent; the cancer cells are most affected. There's no compelling evidence that brewed-tea-level EGCG harms healthy somatic telomere maintenance. Longevity correlations in green-tea-drinking populations are net positive.

5. "Heavy metal contamination — meaningful risk or overblown?"

  • The case: Chinese tea has documented heavy metal issues (32% of samples exceed China's national lead limits per 2016 survey); matcha concentrates whatever's in the leaf.
  • The reassurance: Japan-sourced tea routinely meets stringent food-safety standards. Premium brands publish third-party testing.
  • Practical: Buy Japan-sourced. Skip bulk-bin Chinese GTE. Verify third-party testing on matcha brands (Ippodo, Encha, Nio, Tealyra-Japan, MatchaBar).

6. "Cancer chemoprevention — real or marketing?"

  • Preclinical mechanism is broad and consistent. Human evidence is modest — surrogate marker improvements in a few cohorts (prostate, breast, oral leukoplakia) but no firm mortality endpoints. Polyphenon E doses required for chemoprevention-level effects (400–600 mg/day) push into the hepatotoxicity-risk zone.
  • Practical: Don't oversell EGCG as a cancer drug. As one of several plant compounds in a generally clean diet, modest contribution is plausible.
▸ Verdict change log
  • 2026-05-14 — Verdict: OPTIONAL-ADD / MEDIUM CONFIDENCE. Promoted to thorough research pass. Brewed tea cleanly safe for the user's archetype; isolated extract supplementation only earns a spot during defined cut phases with LFT monitoring. Confidence held at MEDIUM because the hepatotoxicity story is idiosyncratic (HLA-B*35:01-driven) rather than predictable.
  • 2026-05-13 — Initial medium-pass verdict from auto-stub: OPTIONAL-ADD / MEDIUM CONFIDENCE. Same direction; this pass adds depth on pharmacogenomics, HLA-B mechanism, decision matrix, sourcing.
▸ Open questions / gaps Open
  1. HLA-B*35:01 / COMT / UGT1A4 status awaiting 23andMe results (~June 2026). Single biggest gate on whether isolated extract supplementation is appropriate.
  2. Tea vs. extract bioavailability + safety equivalence — no head-to-head RCT comparing daily 2-cup brewed green tea vs equivalent EGCG-dose extract on ALT/AST trajectories. Would settle a lot of the marketing argument.
  3. Long-term (>1 year) high-dose EGCG safety in healthy adults — most RCTs run 8–24 weeks. Minnesota Green Tea Trial (12 months) is one of the longer datasets and was where the COMT/UGT1A4 genotype effect was first quantified.
  4. EGCG + modafinil interaction (real-world clinical magnitude) — theoretical COMT-mediated potentiation; no human study quantifying it. Could be relevant once user starts V5 modafinil.
  5. Matcha-specific risk profile vs. extract — whole-leaf delivery, higher concentration than brewed steeped tea but lower than extract capsules. No dedicated DILI signal in matcha case reports as of 2026, but lack of evidence isn't evidence of safety at high consumption.
  6. Cancer chemoprevention dose-response — what's the minimum effective EGCG dose for clinical chemoprevention benefit, and can it be achieved via tea alone? Open question.
  7. Subconcussive impact + antioxidant role (MMA-specific) — EGCG's antioxidant + anti-inflammatory profile could plausibly support brain recovery from light contact training, but no targeted data exists. Same brain-health open question as for omega-3 and curcumin in this stack.

References

EFSA 2018 — Scientific opinion on the safety of green tea catechins

pubmed.ncbi.nlm.nih.gov · 2018

regulatory cornerstone, 800 mg EGCG/day supplement cap, hepatotoxicity threshold.

View Study

USP comprehensive review of GTE hepatotoxicity 2020 (PMID 32140423)

pubmed.ncbi.nlm.nih.gov · 2020

51 case-report analysis, label-warning update.

View Study

HLA-B*35:01 and green tea-induced liver injury — Hoofnagle et al. 2020

pubmed.ncbi.nlm.nih.gov · 2020

DILIN cohort, 5–7× over-representation in cases.

View Study

Hepatotoxicity with high-dose GTE: COMT and UGT1A4 genotypes — Yu et al. 2022 (PMID 36178169)

pubmed.ncbi.nlm.nih.gov · 2022

Minnesota Green Tea Trial pharmacogenomic substudy.

View Study

Hodgson, Randell, Jeukendrup 2013 — GTE on fat oxidation review

pubmed.ncbi.nlm.nih.gov · 2013

A-tier review of fat-oxidation evidence.

View Study

Mechanism of HLA-B*35:01-mediated EGCG hepatotoxicity — Chem Res Toxicol 2024

pubs.acs.org · 2024

T-cell activation pathway.

View Source

Green tea LiverTox monograph — NCBI Bookshelf NBK547925

ncbi.nlm.nih.gov

clinical reference compiled by NIDDK for DILI clinicians.

View Source

Cognitive Vitality EGCG report (Alzheimer's Drug Discovery Foundation)

alzdiscovery.org

synthesis on cognitive/neuroprotection signals.

View Source

Tamara Rubin 2024–2025 matcha heavy-metal testing

tamararubin.com · 2024

independent third-party heavy-metal testing of commercial matcha brands.

View Source

dopamine.club EGCG community report aggregate

dopamine.club

community dose distribution + stack synergies.

View Source

Latest research

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…
✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸
Loading…